Physician profile
Jon A Peet
NPI 1538323175
$5,706.99
in general payments reported to CMS, 2019-2025
29 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $815 · 2021: $703 · 2022: $484 · 2023: $899 · 2024: $913 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,007.38 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Abbvie INC. | $734.36 | 2022-2025 | |
| Sight Sciences, INC. | $625.88 | 2019-2022 | |
| Allergan, INC. | $461.80 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $378.40 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $335.82 | 2022-2024 | Envista Mx60 Iol, Vyzulta, Toric |
| Apellis Pharmaceuticals, INC. | $314.80 | 2023-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $269.06 | 2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Rxsight INC | $237.03 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Amgen INC. | $219.59 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $210.93 | 2025 | |
| Genentech USA, INC. | $115.97 | 2023-2024 | Vabysmo |
| Rayner Intraocular Lenses Limited | $112.36 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Novartis Pharmaceuticals Corporation | $84.55 | 2019-2022 | |
| New World Medical,INC. | $84.39 | 2023-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.86 | 2019-2021 | |
| Glaukos Corporation | $73.57 | 2023-2025 | Idosetr, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Aerie Pharmaceuticals, INC. | $60.64 | 2021 | |
| Kala Pharmaceuticals, INC. | $52.33 | 2021 | |
| Horizon Therapeutics Plc | $45.20 | 2022-2023 | Tepezza |
| Ocular Therapeutix, INC. | $37.70 | 2023-2025 | Dextenza |
| Omeros Corporation | $34.25 | 2021 | |
| Astellas Pharma US INC | $21.27 | 2025 | Izervay |
| Merz North America, INC. | $20.60 | 2021 | |
| Thea Pharma INC. | $20.40 | 2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Merz Pharmaceuticals, LLC | $18.69 | 2022 | |
| Akorn Operating Company LLC | $15.45 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Peet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.